TTN and myasthenia gravis: Monotherapy with an immunosuppressive agent was used in 53.9 and 55.6% of AChR-MG and AChR+LRP4-MG patients, and immunosuppressive therapy was used in combination therapy with azathioprine or tacrolimus corticosteroids in 56.7% of patients with AChR+Titin-MG.